Spantide I TFA 

Spantide I TFA, a substance P analog, is a selective NK₁ receptor antagonist, with K_i values of 230 nM and 8150 nM for NK₁ and NK₂ receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation^[1][2][3].

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals^[2].
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C₇₅H₁₀₈N₂₀O₁₃.xC₂HF₃O₂

Solid

White to off-white

{D-Arg}-PKPQQ-{D-Trp}-F-{D-Trp}-LL-NH2

CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@H](NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]4N(CCC4)C([C@H](CCCCN)NC([C@H]5N(CCC5)C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800.  [Content Brief]

  [2]. M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8.  [Content Brief]

  [3]. Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807.  [Content Brief]